Significant data on nasal vaccine likely in 2.5 months: Krishna Ella
The Hindu
Clinical trial to pair Covaxin, nasal vaccine doses on cards, says Bharat Biotech founder
Bharat Biotech founder Krishna Ella on July 29 said the company was expecting significant data on its intranasal COVID-19 vaccine to be available in the next two and half months. “In another two to two and a half months, we are going to have significant data,” he said, without committing to a timeline by which the nasal vaccine, whose clinical trials are underway, is likely to be rolled out. Perceived as a game changer in the battle against the virus, the vaccine from the makers of Covaxin promises to deliver multiple benefits, from being more effective, since it is expected to generate immune responses at the site of infection (respiratory mucosa) to ease of administration and production. “It is also easy to scale it up... can produce 100 million doses a month,” Mr. Ella told a FICCI Capital Markets Conference.More Related News